ジアシルグリセロールOアシルトランスフェラーゼ1治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Diacylglycerol O Acyltransferase 1 - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0393
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Diacylglycerol O Acyltransferase 1 – Pipeline Review, H2 2019
Summary

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) – Diglyceride acyltransferase 1 (DGAT-1) is an enzyme that catalyzes the formation of triglycerides from diacylglycerol and Acyl-CoA. It plays a role in esterifying exogenous fatty acids to glycerol. It functions as the major acyl-CoA retinol acyltransferase (ARAT) in the skin, where it acts to maintain retinoid homeostasis and prevent retinoid toxicity leading to skin and hair disorders.

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I and Preclinical stages are 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Dermatology, Gastrointestinal and Metabolic Disorders which include indications Acne Vulgaris, Non-Alcoholic Steatohepatitis (NASH), Hyperlipidemia and Hypertriglyceridemia.

The latest report Diacylglycerol O Acyltransferase 1 – Pipeline Review, H2 2019, outlays comprehensive information on the Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20)
- The report reviews Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics and enlists all their major and minor projects
- The report assesses Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) – Overview
Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) – Companies Involved in Therapeutics Development
Boston Pharmaceuticals Inc
Dermavant Sciences Inc
Sinew Pharma Inc
Viking Therapeutics Inc
Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) – Drug Profiles
BOS-356 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMVT-503 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit DGAT1 for Hyperlipidemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNP-630 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-1430 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) – Dormant Products
Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) – Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Boston Pharmaceuticals Inc, H2 2019
Pipeline by Dermavant Sciences Inc, H2 2019
Pipeline by Sinew Pharma Inc, H2 2019
Pipeline by Viking Therapeutics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

【掲載企業】

Boston Pharmaceuticals Inc
Dermavant Sciences Inc
Sinew Pharma Inc
Viking Therapeutics Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ジアシルグリセロールOアシルトランスフェラーゼ1治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆